Molecules 2017, 22(12), 2096; doi:10.3390/molecules22122096
In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus
1
School of Life Science, Handong Global University, Pohang 37554, Korea
2
Institute of Agricultural Science & Technology, School of Food Science and Biotechnology, Kyungpook National University, Daegu 41566, Korea
3
LegoChem BioSci. Inc., Daejeon 34302, Korea
â€
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 10 November 2017 / Revised: 23 November 2017 / Accepted: 28 November 2017 / Published: 29 November 2017
(This article belongs to the Collection Antibiotics & Superbugs: New Strategies to Combat Antimicrobial Resistance)
Abstract
LCB01-0648 is a novel oxazolidinone compound that shows potent antibacterial activities against most Gram-positive cocci, including the multi-drug resistant Staphylococcus aureus. In this study, in vivo activity of LCB01-0699, a LCB01-0648 prodrug, against S. aureus was evaluated in comparison with that of Linezolid. The results of the systemic infection study demonstrated that LCB01-0699 was more potent than Linezolid against methicillin-susceptible and -resistant S. aureus strains. The in vivo efficacy of LCB01-0699 against methicillin-susceptible and -resistant S. aureus strains in a skin infection model showed more potent activity than Linezolid. LCB01-0699 shows potent in vivo activity against methicillin-susceptible and -resistant S. aureus strains, suggesting that LCB01-0699 would be a novel candidate for the treatment of these infectious diseases caused by S. aureus. View Full-TextKeywords:
LCB01-0699; LCB01-0648; oxazolidinone; in vivo activity; skin infection
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Oh, S.-H.; Park, H.-S.; Lee, J.-H.; Baek, S.-Y.; Chae, S.-E.; Oh, K.; Cho, Y.L.; Kwak, J.-H. In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus. Molecules 2017, 22, 2096.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Related Articles
Article Metrics
Comments
[Return to top]
Molecules
EISSN 1420-3049
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert